Dr. Arteaga is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Road
Dallas, TX 75390Phone+1 214-645-8300
Summary
- Dr. Carlos L. Arteaga is the Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center.
Dr. Arteaga earned his medical degree at the University of Guayaquil in Ecuador. He trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center at San Antonio. He joined Vanderbilt University Medical Center in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served at the Vanderbilt-Ingram Cancer Center (VICC) as Director of the Center for Cancer Targeted Therapies, the Director of the Breast Cancer Program, and the Associate Director for Translational/Clinical Research until 2017, when he joined UT Southwestern.
Dr. Arteaga has more than 300 publications in the areas of oncogenes and breast tumor initiation and progression, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been funded by the National Cancer Institute (NCI), CPRIT, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), and the Susan G. Komen for the Cure and Breast Cancer Research foundations.
During his career, Dr. Arteaga has received several awards, including the American Association for Cancer Research-Richard and Hinda Rosenthal Award, the American Cancer Society Clinical Research Professor Award, the Gianni Bonadonna Award from the American Society of Clinical Oncology, the Brinker Award for Scientific Distinction from the Susan G. Komen Foundation, the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation, and the Clinical Investigator Award from the U.S. Department of Veteran Affairs.
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1988
- Emory University School of MedicineResidency, Internal Medicine, 1980 - 1984
- Universidad de Guayaquil, School of Medicine.Class of 1979
Certifications & Licensure
- TX State Medical License 2018 - 2025
- TN State Medical License 1989 - 2018
- GA State Medical License 1982 - 1989
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Elected Member The American Society for Clinical Investigation, 1999
- Join now to see all
Clinical Trials
- Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Start of enrollment: 2007 Nov 01
Publications & Presentations
PubMed
- Phase II Study of Sunitinib in Tumors WithMutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.Lilian T Gien, Zihe Song, Andrew Poklepovic, Eric A Collisson, James A Zwiebel
JCO Precision Oncology. 2024-12-01 - Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.María Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, Fabiana Napolitano, Chang-Ching Lin
Cancer Letters. 2024-11-01 - Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C.Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz
Clinical Cancer Research. 2024-10-22
Journal Articles
- Effect of Capivasertib in Patients with an AKT1 E17K-Mutated TumorKevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Authored Content
- Buparlisib plus Fulvestrant Versus Placebo plus Fulvestrant for Postmenopausal, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer: Overall Survival Results from BELLE-2October 2018
Press Mentions
- Predicting Treatment Response in Patients with HR-Positive, HER2-Negative Breast CancerDecember 16th, 2024
- Terminated Study’s ‘Challenges’ May Guide Future Trials of MRD-Guided Breast Cancer TherapyDecember 13th, 2024
- Laura J. Van ’T Veer, PhD, Honored with 2024 William L. McGuire Memorial Lecture AwardOctober 15th, 2024
- Join now to see all
Grant Support
- ERBB2 Targeted Antitumor Strategies In Breast CancerNational Cancer Institute1999–2012
- Vanderbilt Training Program In Academic Cancer ResearchNational Cancer Institute2010–2011
- Resistance To Antiestrogen Therapy In Hormone Receptor-Positive Breast CancerNational Cancer Institute2008–2011
- Developmental Research ProgramNational Cancer Institute2008–2011
- Career Development ProgramNational Cancer Institute2008–2011
- Administrative And Outreach CoreNational Cancer Institute2008–2011
- Spore In Breast CancerNational Cancer Institute2003–2011
- Tgf-Betas And Receptors And Human Breast CellsNational Cancer Institute1999–2009
- Training Program In Breast Cancer ResearchNational Cancer Institute2001–2007
- Her(Erbb) Inhibitors In Untreated Operable Breast CancerNational Cancer Institute2004
- Role Of Tgfb-Isoforms In Human Breast Epithelial CellsNational Cancer Institute1995–1998
- Phase I Study Antisense FOS Vector In Breast CancerNational Cancer Institute1996–1997
Professional Memberships
- Member
External Links
- UT Southwesternhttp://profiles.utsouthwestern.edu/profile/146478/carlos-arteaga-biography.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: